Название продукции:2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

IUPAC Name:2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

CAS:1825352-86-0
Молекулярная формула:C14H20BN3O2
Чистота:95%+
Номер в каталоге:CM330195
Молекулярная масса:273.14

Упаковочная единица Доступно для заказа Цена ($) Количество
CM330195-1g in stock ȅŪƐ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:1825352-86-0
Молекулярная формула:C14H20BN3O2
Точка плавления:-
Smiles-код:CC1(C)C(C)(C)OB(C2=NN3C(C(C)=C2)=NC(C)=C3)O1
Плотность:
Номер в каталоге:CM330195
Молекулярная масса:273.14
Точка кипения:
Номер Mdl:
Хранение:

Category Infos

Imidazopyridazines
Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.

Related Products